Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias

被引:11
作者
Da, DZ [1 ]
Yu, F [1 ]
机构
[1] China Pharmaceut Univ, Res Div Pharmacol, Nanjing 210009, Peoples R China
关键词
ion channels; arrhythmia; ryanodine receptor calcium release channel; FKBP12.6; sarcoplasmic reticulum; phospholamban; phosphorylation;
D O I
10.1111/j.1745-7254.2005.00134.x
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The occurrence of cardiac arrhythmias is related to the abnormality of ion channels not only in sarcolemma but also in the sarcoplasmic reticulum, which regulates the process of calcium release and up-take intracellularly. Patterns of ion channelopathy in the sarcolemma can be divided into single channel disorder from gene mutations and multiple channels disorder in a diseased hypertrophied heart. Abnormal RyR2, FKBP12.6, SERCA2a, and PLB are also involved in the initiation of cardiac arrhythmias. Maladjustment by hyperphosphorylation on the ion channels in the sarcolemma and RyR2-FKBP12.6 and SERCA2a-PLB is discussed. Hyperphosphorylation, which is the main abnormality upstream to ion channels, can be targeted for suppressing the deterioration of ion channelopathy in terms of new drug discovery in the treatment and prevention of malignant cardiac arrhythmias.
引用
收藏
页码:918 / 925
页数:8
相关论文
共 50 条
[1]  
ABAUER M, 1998, CARDIOVASC RES, V37, P324
[2]  
Ahmad F, 2003, CLIN INVEST MED, V26, P167
[3]  
[Anonymous], 1989, NEW ENGL J MED, V321, P406
[4]   Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A [J].
Antos, CL ;
Frey, N ;
Marx, SO ;
Reiken, S ;
Gaburjakova, M ;
Richardson, JA ;
Marks, AR ;
Olson, EN .
CIRCULATION RESEARCH, 2001, 89 (11) :997-1004
[5]   The prognostic value of QTc interval and QT dispersion following myocardial infarction in patients treated with or without dofetilide [J].
Brendorp, B ;
Elming, H ;
Jun, L ;
Kober, L ;
Torp-Pedersen, C .
CLINICAL CARDIOLOGY, 2003, 26 (05) :219-225
[6]  
Chen DD, 1996, ACTA PHARMACOL SIN, V17, P516
[7]  
CHEN DD, 1995, CHIN J PHARM TOXICOL, V9, P228
[8]  
COLATSKY TJ, 1995, PHARM NEWS, V2, P17
[9]  
Dai DZ, 1996, DRUG DEVELOP RES, V39, P138, DOI 10.1002/(SICI)1098-2299(199610)39:2<138::AID-DDR5>3.3.CO
[10]  
2-M